Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
Stock épuisé.
En rupture de stock
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
photos non contractuelles
Product description: Recombinant Antibody. Recognizes mouse, bovine and human alpha-tubulin. Species cross-reactivity: Bovine, Human, Mouse. Clone: F2C. Isotype: Human IgG2lambda. Applications: ICC, WB. Host: Purified from HEK 293 cell culture supernatant. Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. Tubulin is the major building block of microtubules. This intracellular cylindrical filamentous structure is present in almost all eukaryotic cells. Microtubules function as structural and mobile elements in mitosis, intracellular transport, flagellar movement, and the cytoskeleton.
Alternate Names/Synonyms:
Product Type: Recombinant Antibody
Clone: F2C
Isotype: Human IgG2lambda
Immunogen: Bovine brain tubulin.
Applications: ICC, WB
Species Crossreactivity: Bovine, Human, Mouse
Specificity: Recognizes mouse, bovine and human alpha-tubulin.
Purity: >95% (SDS-PAGE)
Concentration: 1mg/ml
Formulation: Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Short Term Storage: +4°C
Long Term Storage: -20°C
Shipping: BLUE ICE
Use & Stability: Stable for at least 1 month after receipt when stored at +4°C. Stable for at least 1 year after receipt when stored at -20°C.
Literature References: Recombinant antibodies selected against subcellular fractions to track endogenous protein dynamics in vivo: C. Nizak, et al.; Traffic 7, 739 (2003) | Characterization of single chain antibody targets through yeast two hybrid: O. Vielemeyer, et al; BMC Biotechnol. 10, 59 (2010) | AIM2 inflammasome is activated by pharmacological disruption of nuclear envelope integrity: A. Di Micco, et al.; PNAS 113, e4671 (2016) | Pharmacological eEF2K activation promotes cell death and inhibits cancer progression: A. De Gassart, et al.; EMBO Reports 17, 1471 (2016)
Alerte
Veuillez saisir les champs obligatoires! |